欧洲精品一区二区三区_欧美性性性性_国产一区二区免费在线播放_日日噜噜噜噜人人爽日本精品_无套中出丰满人妻无码_国产偷窥熟女精品视频大全

Chronix Biomedical,  
Chronix生物醫(yī)學(xué)公司是一家分子診斷學(xué)公司，主要開發(fā)癌癥的血液測試，包括伴隨診斷和用于檢測微小殘留病的測試。Chronix生物醫(yī)學(xué)公司正在準(zhǔn)備通過它自己的CLIA認(rèn)證實(shí)驗(yàn)室提供它的開創(chuàng)性的測試。該公司的最初產(chǎn)品是將會(huì)被癌癥治療中心和腫瘤學(xué)家在治療癌癥病人的時(shí)候使用的一種測試。Chronix生物醫(yī)學(xué)公司是一家私營公司，總部設(shè)在加利福尼亞州的圣何塞，實(shí)驗(yàn)室設(shè)在德國哥廷根以及美國南達(dá)科他州的布魯金斯。它是第一家對無細(xì)胞DNA使用下一代測序技術(shù)的公司。該公司擁有兩個(gè)檢測無細(xì)胞DNA和RNA的已批準(zhǔn)的專利，以及使用下一代測序技術(shù)用于檢測乳腺癌、前列腺癌和結(jié)直腸癌的4個(gè)正在申請的專利。

Chronix Biomedical, Inc. is a molecular diagnostics company developing blood tests primarily for monitoring minimal residual disease (MRD) in cancer patients. Chronix will offer its pioneering tests through its own CLIA certified laboratories expected to open in 2015. The value proposition of the Chronix MRD test is that it:
1) Reduces costs by saving money on unnecessary treatments and more importantly treating cancer recurrences earlier in patients.
2) Improves quality in healthcare by treating a patients recurrences of cancer as earlier as possible. In addition, it eliminates unnecessary treatments to patients.
3) Increases access to healthcare because a patient can have their blood drawn at any blood-drawing station or in their physician's office and sent to the Chronix laboratory.
Chronix is privately held with headquarters in San Jose, California, and laboratories in G?ttingen, Germany and Brookings, South Dakota.